Evidence map›Paper›PMID 34898373›Full record

Trial reportBioengineered2022

MicroRNA (miR)-590-3p alleviates high-glucose induced renal tubular epithelial cell damage by targeting C-X3-C motif chemokine ligand 1 (CX3CL1) in diabetic nephropathy.

Jie Yun, Jinyu Ren, Yufei Liu, Lijuan Dai, Liqun Song, Xiaopeng Ma, Shan Luo, Yexu Song

Open access · goldAbstract readClinical TrialVideo-Audio Media
In one paragraph

Trial report in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. miRNAs as Biomarkers in Diabetes: Moving towards Precision Medicine.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jie YunDepartment of Nephrology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang, China.
Jinyu RenDepartment of Encephalopathy, Second Hospital Affiliated to Heilongjiang University of Chinese Medicine, Heilongjiang, China.
Yufei LiuDepartment of Blood Purification, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang, China.
Lijuan DaiDepartment of Nephrology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang, China.
Liqun SongDepartment of Nephrology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang, China.
Xiaopeng MaDepartment of Nephrology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang, China.
Shan LuoDepartment of Nephrology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang, China.
Yexu SongDepartment of Science and Technology, Heilongjiang University of Chinese Medicine, Heilongjiang, China.ORCID 0000-0001-9458-565X
First Affiliated Hospital of Heilongjiang University of Chinese Medicine · CNHeilongjiang University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We attempted to analyze the clinical value of microRNA (miR)-590-3p in diabetic nephropathy (DN) patients and its role in high glucose (HG)-induced renal tubular epithelial cell (HK-2) injury. Serum levels of miR-590-3p were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Spearman correlation coefficient analysis of the correlation between miR-590-3p and clinical indicators. The diagnostic value of miR-590-3p was analyzed by the receiver operating characteristic (ROC) curve. Then, the DN cell model induced by HG in HK-2 cells was established. Enzyme-linked immunosorbent assay (ELISA), flow cytometry, and CCK-8 assay were employed to assess cell inflammation, oxidative stress, apoptosis, and proliferation. Dual-luciferase reporter assay confirmed the target of miR-590-3p. Serum miR-590-3p was reduced in patients of DN, which was positively correlated with eGFR and negatively associated with albuminuria. Furthermore, miR-590-3p also can diagnose patients of DN from healthy subjects or patients of T2DM. Furthermore, miR-590-3p was decreased in a concentration- and time-dependent manner during HG-induction. miR-590-3p overexpression bated HG-induced inhibition effect on cell proliferation and promotion effects on apoptosis, oxidative stress, and inflammation. C-X3-C motif chemokine ligand1 (CX3CL1) is the target of miR-590-3p, whose levels were enhanced in DN patients and are negatively regulated by miR-590-3p. Our discoveries offered new insights that reduced miR-590-3p as a potential biomarker for the diagnosis of DN, and elevated miR-590-3p can alleviate renal tubular injury by HG-induced through targeting CX3XL1, which may be a novel target for improving the development of DN.

Indexed as

AdultAgedCell LineChemokine CX3CL1Diabetic NephropathiesEpithelial CellsFemaleGlucoseHumansKidney TubulesMaleMicroRNAsMiddle AgedChemokine CX3CL1CX3CL1 protein, humanGlucoseMicroRNAsMIRN590 microRNA, humandiabetic nephropathyMir-590-3prenal tubule injury

Identifiers

PMID34898373
PMCPMC8805927
OpenAlexW4200100009

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.